Costs and Treatment Patterns Among Patients with Atopic Dermatitis Using Advanced Therapies in the United States: Analysis of a Retrospective Claims Database.

Lawrence F EichenfieldMarco daCosta DiBonaventuraJason XenakisMarie-Helene LafeuilleMei Sheng DuhIman FakihMark LevenbergJoseph C CappelleriVanja Sikirica

Published in: Dermatology and therapy (2020)

Switching to combination therapy with SCSs and TCSs was common within 6 months of initiating advanced therapy in patients with AD. Patients also incurred significant pharmacy and outpatient costs. These results highlight the difficulty of managing AD with these existing treatment options.

Keyphrases

combination therapy
end stage renal disease
atopic dermatitis
ejection fraction
newly diagnosed
peritoneal dialysis
prognostic factors
stem cells
bone marrow
mesenchymal stem cells
cell therapy